News Image

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

Provided By GlobeNewswire

Last update: Apr 16, 2025

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa

Read more at globenewswire.com

BIOVIE INC

NASDAQ:BIVI (10/24/2025, 8:10:59 PM)

After market: 1.9021 +0.02 (+1.18%)

1.88

-0.01 (-0.53%)



Find more stocks in the Stock Screener

Follow ChartMill for more